In this issue:
Indatuximab ravtansine for multiple myeloma
Daratumumab in non-Hodgkin lymphoma subtypes
Safety and efficacy of daratumumab outside clinical trials
Long-term idelalisib in relapsed chronic lymphocytic leukaemia
Emicizumab prophylaxis every 4 weeks for haemophilia A
Rituximab in aggressive B-cell lymphoma
Mogamulizumab in relapsed/refractory adult T-cell leukaemia/lymphoma
Long-term follow-up of ibrutinib for chronic lymphocytic leukaemia
Rituximab originator vs biosimilar in immune-mediated TTP
Siltuximab for high-risk smouldering multiple myeloma
Please login below to download this issue (PDF)